John M Regan

7329675, Feb 12, 2008

Sep 1, 2004

10/933077

Paul Joseph Cox - Flemington NJ, US
Shelley Bower - Bedminster NJ, US
David John Aldous - Gillette NJ, US
Peter Charles Astles - Kent, GB
Daniel Gerard McGarry - Branchburg NJ, US
Christopher Hulme - Phoenixville PA, US
John Robinson Regan - Larchmont NY, US
Fu-Chih Huang - Belle Mead NJ, US
Stevan Wakefield Djuric - Libertyville PA, US
Kevin Joseph Moriarty - Norristown PA, US
Rose Mappilakunnel Mathew - Collegeville PA, US
Gregory Bernard Poli - Bethlehem PA, US

Aventis Pharma Limited - West Malling

A61K 31/44
A61K 43/40
C07D 405/00

5142844, 514339, 5462821

This invention is directed to physiologically active compounds of formula (I)Such compounds inhibit the production or physiological effects of TNF and inhibit cyclic AMP phosphodiesterase. The invention is also directed to pharmnaceutical compositions comprising compoundS of formula (I), their phatmaceUtical use and methods for their preparation.

48639575, Sep 5, 1989

Dec 21, 1987

7/135805

Kent W. Neuenschwander - Ambler PA
John R. Regan - Princeton NJ
Benedict J. Kosmider - Audubon PA

Rorer Pharmaceutical Corporation - Fort Washington PA

A61K 31365
C07D30920

514460

Disclosed are novel 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors useful as antihypercholesterolemic agents represented by the formula ##STR1## and the corresponding ring-opened hydroxy acids derived therefrom and pharmaceutically acceptable salts thereof. Pharmaceutical compositions containing said compounds and method of inhibiting the biosynthesis of cholesterol therewith are also disclosed.

49391437, Jul 3, 1990

Sep 25, 1989

7/412356

John R. Regan - Princeton NJ
Joseph G. Bruno - Sellersville PA
Kent W. Neuenschwander - Ambler PA

Rorer Pharmaceutical Corporation - Fort Washington PA

A61K 31345
C07D40502

514326

Disclosed are novel 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors useful as antihypercholesterolemic agents represented by the formula ##STR1## and the corresponding ring-opened hydroxy acids derived therefrom and pharmaceutically acceptable salts thereof. Pharmaceutical compositions containing said compounds and method of inhibiting the biosynthesis of cholesterol therewith are also disclosed.

50011448, Mar 19, 1991

Apr 17, 1990

7/510351

John R. Regan - Princeton NJ
Kent W. Neuenschwander - Ambler PA

Rhone-Poulenc Rorer Pharmaceuticals Inc. - Fort Washington PA

A61K 31385
C07D33908

514436

Disclosed are novel 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors useful as antihypercholesterolemic agents represented by the formula ##STR1## and the corresponding ring-opened hydroxy acids derived therefrom and pharmaceutically acceptable salts thereof. Phamaceutical compositions containing said compounds and method of inhibiting the biosynthesis of cholesterol therewith are also disclosed.

49046926, Feb 27, 1990

Dec 12, 1988

7/283111

John R. Regan - Princeton NJ
Josehp G. Bruno - Sellersville PA
Kent W. Neuenschwander - Ambler PA
Donald E. Kuhla - Doylestown PA

Rorer Pharmaceutical Corporation - Fort Washington PA

A61K 31365
C07D30930

514459

Disclosed are novel 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors useful as antihypercholesterolemic agents represented by the formula ##STR1## and the corresponding ring-opened hydroxy acids derived therefrom and pharmaceutically acceptable salts thereof. Pharmaceutical compositions containing said compounds and method of inhibiting the biosynthesis of cholesterol therewith are also disclosed.

56744820, Oct 7, 1997

Aug 9, 1991

7/742794

John R. Regan - Princeton NJ
Michael N. Chang - Newtown PA
Jack Newman - Warrington PA
Schmuel Ben-Sasson - Jerusalem, IL

Rhone-Poulenc Rorer Pharmaceuticals, Inc. - Collegeville PA

A61K 31775
C08G 804

424 7837

A biologically active polymeric compound comprising an alkylaryl or heteroalkylaryl backbone having about 5 to about 50 repeating aromatic ring-containing units and which, according to the computer program marketed as SYBYL. RTM. version 5. 2 running on a DEC VAX. RTM. 11/750 computer, is capable of forming a linear backbone having a helical secondary structure, and wherein the maximum diameter of the helical structure, as measured by the alkylaryl or heteroalkylaryl backbone, is less than 3 times greater than the maximum diameter of the aryl group of the alkylaryl or heteroalkylaryl backbone.

49944940, Feb 19, 1991

Dec 14, 1989

7/450493

John R. Regan - Princeton NJ
Joseph G. Bruno - Sellersville PA
Kent W. Neuenschwander - Ambler PA
Donald E. Kuhla - Doylestown PA

Rhone-Poulenc Rorer Pharmaceuticals Inc. - Fort Washington PA

A61K 3119
C07C 6222
C07C 6232

514569

Disclosed are novel 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors useful as antihypercholesterolemic agents represented by the formula ##STR1## and the corresponding ring-opened hydroxy acids derived therefrom and pharmaceutically acceptable salts thereof. Pharmaceutical compositions containing said compounds and method of inhibiting the biosynthesis of cholesterol therewith are also disclosed.

51323125, Jul 21, 1992

Nov 27, 1990

7/618754

John R. Regan - Princeton NJ
Kent E. Neuenschwander - Ambler PA

Rhone-Poulenc Rorer Pharmaceuticals Inc. - Collegeville PA

A61K 3117
A61K 31365
C07D21516
C07D30910

514312

Disclosed are novel 3-hydroxy-3-methylglutarylcoenzyme A reductase inhibitors useful as antihypercholesterolemic agents represented by the formula ##STR1## and the corresponding ring-opened hydroxy acids derived therefrom and pharmaceutically acceptable salts thereof. Pharmaceutical compositions containing said compounds and method of inhibiting the biosynthesis of cholesterol therewith are also disclosed.